ITCI logo

Intra-Cellular Therapies (ITCI)

Profile

Full Name

Intra-Cellular Therapies, Inc.

Ticker Symbol

ITCI

Exchange

NASDAQ

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

United States

IPO

January 7, 2014

Indexes

Not included

Website

http://www.intracellulartherapies.com

Employees

860

Key Details

Price

$131.92

Market Cap

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$680.50M(+47.24% YoY)

Annual EPS

-$0.72(+50.68% YoY)

PE Ratio

-

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$131.92
ITCI price is $131.92

Price All-time High

$131.93
ITCI price is currently -0.01% below its historical high of $131.93

Price Most Recent Change

-0.01%
ITCI price was down -0.01% on Apr 1, 2025

Price YTD Change

+58.03%
ITCI price is up +58.03% since January 1st

Price 1-year Change

+93.23%
ITCI price is up +93.23% year-on-year

Price 3-year Change

+110.47%
ITCI price is up +110.47% over the past 3 years

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market Cap

$14.03B
ITCI market capitalization is $14.03 billion

Market Cap 3-year Change

+138.35%
ITCI market capitalization is up +138.35% over the past 3 years

Market Cap All-time High

$14.03B
ITCI market capitalization is currently -0.01% below its historical high of $14.03 billion

Market Cap Sector Rank

94.75%
ITCI market capitalization is higher than 94.75% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+9.08%
ITCI shares outstanding is up +9.08% year-on-year

Shares Outstanding 3-Year Change

+13.09%
ITCI shares outstanding is up +13.09% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.26
ITCI beta is 0.26

200-day SMA

$92.35
ITCI price is currently +42.85% above its 200-day simple moving average

50-day SMA

$129.31
ITCI price is currently +2.02% above its 50-day simple moving average

RSI

84.56
ITCI 14-day relative strength index is 84.56

Volume

6.65
ITCI 30-day relative volume is 6.65

ATR

$0.27
ITCI average true range is $0.27

10-day Historical Volatility

0.58%
ITCI 10-day historical volatility is 0.58%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$680.50M
ITCI annual revenue is $680.50 million

Revenue Analysts Estimate

$950.31M
ITCI annual revenue is currently -28.39% lower than the consensus analysts' forecast

Revenue 1-year Change

+47.24%
ITCI annual revenue is up +47.24% year-on-year

Revenue Sector Rank

77.09%
ITCI annual revenue is higher than 77.09% of companies in Healthcare sector

EPS

EPS

-$0.72
ITCI annual earnings per share is -$0.72

EPS Analysts Estimate

$0.13
ITCI annual earnings per share is currently -673.25% lower than the consensus analysts' forecast

EPS 1-year Change

+50.68%
ITCI annual earnings per share is up +50.68% year-on-year

EPS Sector Rank

63.11%
ITCI annual earnings per share is higher than 63.11% of companies in Healthcare sector

Profit

Gross Profit

$623.54M
ITCI annual gross profit is $623.54 million

Gross Margin

91.63%
ITCI annual gross profit margin is 91.63%

Operating Profit

-$116.72M
ITCI annual operating income is -$116.72 million

Operating Margin

-17.15%
ITCI annual operating profit margin is -17.15%

Net Income

-$74.68M
ITCI annual net profit is -$74.68 million

Net Margin

-10.97%
ITCI annual net profit margin is -10.97%

Expenses

Total Expenses

$797.22M
ITCI annual total expenses is $797.22 million

Operating Expenses

$740.26M
ITCI annual total operating expenses is $740.26 million

Cost Of Goods Sold

$56.96M
ITCI annual cost of goods sold is $56.96 million

Selling, General & Administrative Expenses

$504.49M
ITCI annual SGA is $504.49 million

Depreciation And Amortization

$508.00K
ITCI annual depreciation & amortization is $508.00 thousand

Interest Expense

-
ITCI annual interest expense value is unknown

Income Tax

$473.00K
ITCI annual income tax is $473.00 thousand

EBIT & EBITDA

EBIT

-$116.72M
ITCI annual earnings before interest & taxes is -$116.72 million

EBITDA

-$116.21M
ITCI annual EBITDA is -$116.21 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total Assets

$1.37B
ITCI annual total assets is $1.37 billion

Non Current Assets

$59.55M
ITCI annual long term assets is $59.55 million

Current Assets

$1.31B
ITCI annual total current assets is $1.31 billion

Cash And Cash Equivalents

$306.95M
ITCI annual cash & cash equivalents is $306.95 million

Accounts Receivable

$166.50M
ITCI annual accounts receivable is $166.50 million

Inventory

$26.28M
ITCI annual inventory is $26.28 million

Liabilities

Total Liabilities

$218.45M
ITCI annual total liabilities is $218.45 million

Long Term Liabilities

$12.75M
ITCI annual total long term liabilities is $12.75 million

Current Liabilities

$205.70M
ITCI annual total current liabilities is $205.70 million

Accounts Payable

$26.07M
ITCI annual accounts payable is $26.07 million

Debt

Total Debt

$16.98M
ITCI annual total debt is $16.98 million

Total Debt 1-year Change

+0.25%
ITCI annual total debt is up +0.25% year-on-year

Long Term Debt

$12.75M
ITCI annual long term debt is $12.75 million

Short Term Debt

$4.23M
ITCI annual short term debt is $4.23 million

Equity & Capital

Shareholders Equity

$1.15B
ITCI annual stockholders equity is $1.15 billion

Book Value

$1.15B
ITCI annual book value is $1.15 billion

Retained Earnings

-$1.69B
ITCI annual retained earnings is -$1.69 billion

Working Capital

$1.10B
ITCI annual working capital is $1.10 billion

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash From Operations

-$73.18M
ITCI annual cash flow from operations is -$73.18 million

Cash From Operations 1-year Change

+41.08%
ITCI annual cash flow from operations is up +41.08% year-on-year

Cash From Investing

-$335.15M
ITCI annual cash flow from investing activities is -$335.15 million

Cash From Investing 1-year Change

-417.55%
ITCI annual cash flow from investing activities is down -417.55% year-on-year

Cash From Financing

$567.51M
ITCI annual cash flow from financing activities is $567.51 million

Cash From Financing 1-year Change

+3086.46%
ITCI annual cash flow from financing activities is up +3086.46% year-on-year

CAPEX

CAPEX

$322.00K
ITCI annual capital expenditures is $322.00 thousand

CAPEX 1-year Change

+19.7%
ITCI annual capital expenditures is up +19.7% year-on-year

Free Cash Flow

Free Cash Flow

-$73.50M
ITCI annual free cash flow is -$73.50 million

Free Cash Flow 1-year Change

+40.95%
ITCI annual free cash flow is up +40.95% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross Margin

91.63%
ITCI annual gross profit margin is 91.63%

Operating Margin

-17.15%
ITCI annual operating profit margin is -17.15%

Net Margin

-10.97%
ITCI annual net profit margin is -10.97%

ROA & ROE

ROA

-7.13%
ITCI annual return on assets is -7.13%

ROE

-8.58%
ITCI annual return on equity is -8.58%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
ITCI price to earnings ratio value is unknown

PE Ratio Sector Rank

-
ITCI price to earnings ratio is unknown

PB Ratio

PB Ratio

12.21
ITCI price to book ratio is 12.21

PB Ratio Sector Rank

93.84%
ITCI price to book ratio is higher than 93.84% of companies in Healthcare sector

PS Ratio

PS Ratio

20.61
ITCI price to sales ratio is 20.61

PS Ratio Sector Rank

86.98%
ITCI price to sales ratio is higher than 86.98% of companies in Healthcare sector

Enterprise value

Enterprise Value

$13.74B
ITCI enterprise value is $13.74 billion

Enterprise Value Sector Rank

93.56%
ITCI enterprise value is higher than 93.56% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-118.20
ITCI EV/EBITDA is -118.20

EV/EBITDA Sector Rank

0.96%
ITCI EV/EBITDA is higher than 0.96% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current Ratio

6.36
ITCI annual current ratio is 6.36

Quick Ratio

6.23
ITCI annual quick ratio is 6.23

Leverage

Debt To Equity

0.00
ITCI annual debt to equity ratio is 0.00

Interest Coverage Ratio

-
ITCI annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

3
ITCI piotroski f-score is 3

Altman Z-Score

37.98
ITCI altman z-score is 37.98

Analyst ratings

Recent major analysts updates

Feb 24, 25 Mizuho
Neutral
Feb 21, 25 Needham
Hold
Jan 31, 25 Canaccord Genuity
Hold
Jan 22, 25 RBC Capital
Sector Perform
Jan 14, 25 Piper Sandler
Neutral
Jan 13, 25 Needham
Hold
Nov 4, 24 JP Morgan
Overweight
Oct 31, 24 Needham
Buy
Oct 30, 24 Needham
Buy
Oct 11, 24 Morgan Stanley
Overweight

Institutional Ownership

Similar stocks

UTHR logo
United Therapeutics (UTHR)
HOLX logo
Hologic (HOLX)
SMMT logo
Summit Therapeutics (SMMT)
RPRX logo
Royalty Pharma (RPRX)
ICLR logo
ICON Public Limited (ICLR)
FMS logo
Fresenius Medical Care AG & Co KGaA (FMS)
INSM logo
Insmed Incorporated (INSM)
BMRN logo
BioMarin Pharmaceutical (BMRN)
SOLV logo
Solventum (SOLV)
  • What is the ticker symbol for Intra-Cellular Therapies?
  • Does Intra-Cellular Therapies pay dividends?
  • What sector is Intra-Cellular Therapies in?
  • What industry is Intra-Cellular Therapies in?
  • What country is Intra-Cellular Therapies based in?
  • When did Intra-Cellular Therapies go public?
  • Is Intra-Cellular Therapies in the S&P 500?
  • Is Intra-Cellular Therapies in the NASDAQ 100?
  • Is Intra-Cellular Therapies in the Dow Jones?
  • When was Intra-Cellular Therapies's last earnings report?
  • When does Intra-Cellular Therapies report earnings?
  • Should I buy Intra-Cellular Therapies stock now?

What is the ticker symbol for Intra-Cellular Therapies?

The ticker symbol for Intra-Cellular Therapies is NASDAQ:ITCI

Does Intra-Cellular Therapies pay dividends?

No, Intra-Cellular Therapies does not pay dividends

What sector is Intra-Cellular Therapies in?

Intra-Cellular Therapies is in the Healthcare sector

What industry is Intra-Cellular Therapies in?

Intra-Cellular Therapies is in the Drug Manufacturers - Specialty & Generic industry

What country is Intra-Cellular Therapies based in?

Intra-Cellular Therapies is headquartered in United States

When did Intra-Cellular Therapies go public?

Intra-Cellular Therapies's initial public offering (IPO) was on January 7, 2014

Is Intra-Cellular Therapies in the S&P 500?

No, Intra-Cellular Therapies is not included in the S&P 500 index

Is Intra-Cellular Therapies in the NASDAQ 100?

No, Intra-Cellular Therapies is not included in the NASDAQ 100 index

Is Intra-Cellular Therapies in the Dow Jones?

No, Intra-Cellular Therapies is not included in the Dow Jones index

When was Intra-Cellular Therapies's last earnings report?

Intra-Cellular Therapies's most recent earnings report was on Feb 21, 2025

When does Intra-Cellular Therapies report earnings?

The next expected earnings date for Intra-Cellular Therapies is May 7, 2025

Should I buy Intra-Cellular Therapies stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page